319 related articles for article (PubMed ID: 37228488)
1. Liquid biopsies and minimal residual disease in lymphoid malignancies.
Bou Zerdan M; Kassab J; Saba L; Haroun E; Bou Zerdan M; Allam S; Nasr L; Macaron W; Mammadli M; Abou Moussa S; Chaulagain CP
Front Oncol; 2023; 13():1173701. PubMed ID: 37228488
[TBL] [Abstract][Full Text] [Related]
2. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsies and minimal residual disease in myeloid malignancies.
Allam S; Nasr K; Khalid F; Shah Z; Khan Suheb MZ; Mulla S; Vikash S; Bou Zerdan M; Anwer F; Chaulagain CP
Front Oncol; 2023; 13():1164017. PubMed ID: 37213280
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
Romano A; Palumbo GA; Parrinello NL; Conticello C; Martello M; Terragna C
Front Oncol; 2019; 9():699. PubMed ID: 31482061
[TBL] [Abstract][Full Text] [Related]
6. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
7. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies.
Dogliotti I; Drandi D; Genuardi E; Ferrero S
J Clin Med; 2018 Sep; 7(9):. PubMed ID: 30231510
[TBL] [Abstract][Full Text] [Related]
8. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
9. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM; Del Giudice I; Della Starza I; Soscia R; Cavalli M; Cola M; Bellomarino V; Di Trani M; Guarini A; Foà R
Front Oncol; 2023; 13():1152467. PubMed ID: 36998457
[TBL] [Abstract][Full Text] [Related]
10. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
11. Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium.
Krzywdzińska A; Puła B; Czyż A; Krzymieniewska B; Kiernicka-Parulska J; Mierzwa A; Szymczak D; Milanowska A; Kiraga A; Kwiecień I; Zaleska J; Jamroziak K
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679569
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.
Riva G; Nasillo V; Ottomano AM; Bergonzini G; Paolini A; Forghieri F; Lusenti B; Barozzi P; Lagreca I; Fiorcari S; Martinelli S; Maffei R; Marasca R; Potenza L; Comoli P; Manfredini R; Tagliafico E; Trenti T; Luppi M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572809
[TBL] [Abstract][Full Text] [Related]
13. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
15. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
16. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
19. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
[TBL] [Abstract][Full Text] [Related]
20. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
